Verastem Oncology’s Collaboration With Mirati Therapeutics

Ropes & Gray advised Verastem Oncology in the deal.

Verastem Oncology announced a collaboration to evaluate Mirati Therapeutics’ investigational KRAS inhibitor drug with Verastem’s investigational inhibitor drug in combination for mutant non-small cell lung cancer. 

Mirati Therapeutics Inc., is a clinical-stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. The company is relentlessly focused on bringing forward therapies that address areas of high unmet need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer. 

Verastem Oncology (Nasdaq: VSTM) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Its pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and focal adhesion kinase (FAK) inhibition. 

The Ropes & Gray team was led by life sciences partner Abigail Gregor (Picture) and life sciences associate Amanda White (both of Boston).

Involved fees earner: Abigail Gregor – Ropes & Gray; Amanda White – Ropes & Gray;

Law Firms: Ropes & Gray;

Clients: Verastem, Inc (Verastem Oncology);